Formosa and Adalvo License Clobetasol Propionate for Eye Inflammation and Pain Treatment

TAIPEI, May 28, 2025 — Formosa Pharmaceuticals, a biotechnology firm based in Taiwan, has signed an exclusive licensing agreement with Adalvo Limited to commercialize its ophthalmic suspension, APP13007, in the European and Brazilian markets. This innovative treatment aims to alleviate post-operative inflammation and pain following eye surgery. Adalvo, established in 2018, is a prominent pharmaceutical company known for its flexible and innovative approach to market access. It has successfully launched nearly 1100 drugs with the support of over 170 commercial partners in more than 130 countries.

The agreement between Formosa and Adalvo includes various financial arrangements such as an upfront payment, sales milestones, and profit sharing. APP13007 is formulated with clobetasol propionate, a potent corticosteroid, using Formosa's proprietary APNT® nanoparticle technology. This formulation, approved by the US FDA in 2024, offers a convenient twice-daily dosing for 14 days, ensuring rapid and sustained pain relief. A survey conducted among 100 ophthalmic surgeons in the US highlighted the medication's swift pain resolution and minimal adverse effects as significant reasons for its recommendation.

The European ophthalmology market reached $16 billion in 2024, with Germany and the UK leading as major contributors. Cataract surgeries are among the most frequent procedures in EU hospitals, resulting in high demand for effective post-operative treatments. The ocular surgery sector is anticipated to expand significantly, reaching $38 billion by 2032.

Erick Co, President and CEO of Formosa Pharmaceuticals, expressed enthusiasm about the partnership with Adalvo, acknowledging their strong presence and expertise in European markets. He emphasized the recognition of APP13007 as a valuable addition to Adalvo's diverse portfolio of innovative medications. Anil Okay, CEO of Adalvo, reiterated the company's commitment to expanding access to novel treatments across key therapeutic areas and expressed satisfaction in joining forces with Formosa to introduce this important ophthalmic product to new markets.

Formosa Pharmaceuticals, Inc. focuses on ophthalmology and oncology, utilizing its proprietary nanoparticle formulation technology (APNT®) to enhance the dissolution and bioavailability of active pharmaceutical ingredients (APIs) for topical, oral, and inhalation applications. This technology addresses challenges related to the safety, delivery, and penetration of potent drug agents.

Adalvo, a globally recognized pharmaceutical company, has established itself as a leading B2B entity in Europe with an extensive network of commercial partnerships. Driven by a commitment to delivering high-quality, differentiated products, Adalvo aims to make a positive impact on patients worldwide. The company's dedication to excellence and its dynamic leadership have solidified its reputation as a reliable partner in the industry.